Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00109502" target="_blank" >RIV/00216224:14110/19:00109502 - isvavai.cz</a>
Result on the web
<a href="http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract" target="_blank" >http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2018.213157" target="_blank" >10.3324/haematol.2018.213157</a>

Result language
angličtina
Original language name
Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement.
Original language description
Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
Czech name
—
Czech description
—

Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/LM2015090" target="_blank" >LM2015090: Czech National Node to the European Clinical Research Infrastructure Network</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)